Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Palatin Technologies Inc (PTN)
NYSE MKT:PTN
Holding PTN?
Track your performance easily
PTN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.68 - $5.65
Previous Close$1.13
Volume138.15K
Average Volume (3M)285.56K
Market Cap
$22.09M
Enterprise Value$23.67M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$1.58M
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Feb 18, 2025EPS Estimate
-$0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.97
Shares Outstanding19,548,167
10 Day Avg. Volume220,464
30 Day Avg. Volume285,559
Standard Deviation0.26
R-Squared0.03
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)-2.34
Price to Sales (P/S)7.63
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.72
Enterprise Value/Gross Profit5.34
Enterprise Value/Ebitda-0.62
Forecast
1Y Price Target
$11.50Price Target Upside908.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Palatin Technologies News
PremiumCompany Announcements
Palatin Technologies Shifts Focus to Obesity Treatments
Bulls Say, Bears Say
Bulls Say
Clinical Trials And Drug DevelopmentPalatin completes Phase 2 enrollment for PL8177 in ulcerative colitis, indicating progress in their clinical trial efforts.
Obesity Treatment InnovationsAn orally active small-molecule MC4R agonist could offer a promising solution for patients with obesity, addressing a significant unmet medical need.
Partnerships And Market InterestThere has been reported interest from multiple parties for Palatin's Phase 3 dry eye disease program and other early-stage programs.
Bears Say
Earnings PerformancePalatin announced F1Q25 financial results, posting an EPS of ($0.39), indicating a negative earnings performance.
Regulatory ChallengesAchieving statistical significance in both co-primary efficacy endpoints (one for signs and one for symptoms) will be the critical challenge Palatin must overcome to secure a Phase 3 win and bolster its NDA for potential FDA approval.
Strategic ShiftThe company's decision to out-license PL8177 suggests a strategic shift away from this program, focusing more on obesity research.
---
Ownership Overview
3.89% Insiders
3.67% Mutual Funds
0.77% Other Institutional Investors
88.51% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PTN FAQ
What was Palatin Technologies Inc’s price range in the past 12 months?
Palatin Technologies Inc lowest stock price was $0.68 and its highest was $5.65 in the past 12 months.
What is Palatin Technologies Inc’s market cap?
Currently, no data Available
When is Palatin Technologies Inc’s upcoming earnings report date?
Palatin Technologies Inc’s upcoming earnings report date is Feb 18, 2025 which is in 80 days.
How were Palatin Technologies Inc’s earnings last quarter?
Currently, no data Available
Is Palatin Technologies Inc overvalued?
According to Wall Street analysts Palatin Technologies Inc’s price is currently Undervalued.
Does Palatin Technologies Inc pay dividends?
Palatin Technologies Inc does not currently pay dividends.
What is Palatin Technologies Inc’s EPS estimate?
Palatin Technologies Inc’s EPS estimate is -$0.42.
How many shares outstanding does Palatin Technologies Inc have?
Palatin Technologies Inc has 19,548,166 shares outstanding.
What happened to Palatin Technologies Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Palatin Technologies Inc?
Among the largest hedge funds holding Palatin Technologies Inc’s share is Fortress Investment Group LLC. It holds Palatin Technologies Inc’s shares valued at 314.
---
Palatin Technologies Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.50 (908.77% Upside)
$11.50 (908.77% Upside)
Blogger Sentiment
Bullish
PTN Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.14%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-69.64%
Trailing 12-Months
Company Description
Palatin Technologies Inc
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.
---
PTN Earnings Call
Q1 2024
0:00 / 0:00
---
PTN Stock 12 Month Forecast
Average Price Target
$11.50
▲(908.77% Upside)
Technical Analysis
Aclaris Therapeutics
―
Clearside Biomedical
―
TuHURA Biosciences
―
TRACON Pharmaceuticals
―
Best Analysts Covering PTN
1 Year
1 Year Success Rate
5/24 ratings generated profit
1 Year Average Return
-35.72%
reiterated a buy rating 7 months ago
Copying Michael Higgins's trades and holding each position for 1 Year would result in 20.83% of your transactions generating a profit, with an average return of -35.72% per trade.
---